T2 Biosystems, Inc. (LON: 0A57)

Market Cap	3.92M
Revenue (ttm)	5.73M
Net Income (ttm)	-32.05M
Shares Out	n/a
EPS (ttm)	-3.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,972
Average Volume	13,234
Open	0.220
Previous Close	0.249
Day's Range	0.220 - 0.240
52-Week Range	0.263 - 5.613
Beta	n/a
RSI	25.63
Earnings Date	Feb 14, 2025

About T2 Biosystems

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnosti...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2006
• Employees: 113
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A57

Financial Performance

In 2023, T2 Biosystems's revenue was $7.19 million, a decrease of -67.75% compared to the previous year's $22.31 million. Losses were -$50.08 million, -19.66% less than in 2022.

Financial numbers in USD